$Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose$

Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose

<b>Background and Aim:</b> Controlling the hepatic inflammation of metabolic dysfunction-associated steatotic liver disease (MASLD) is important to prevent serious condition. Pemafibrate, a selective peroxisome proliferator-activated receptor-α modulator, has demonstrated effectiveness a...

书目详细资料
Main Authors:	Satoshi Shinozaki, Kouichi Miura, Toshiyuki Tahara, Hironori Yamamoto
格式:	文件
语言:	English
出版:	MDPI AG 2025-02-01
丛编:	Metabolites
主题:	non-alcoholic fatty liver disease non-alcoholic steatohepatitis pemafibrate dyslipidemia metabolic dysfunction-associated steatotic liver disease
在线阅读:	https://www.mdpi.com/2218-1989/15/2/100

相似书籍

Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study
由: Satoshi Shinozaki, et al.
出版: (2023-06-01)

Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up
由: Suguru Ikeda, et al.
出版: (2021-12-01)

Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study
由: Hiroki Ono, et al.
出版: (2024-04-01)

Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD
由: Takanobu Iwadare, et al.
出版: (2022-11-01)

Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
由: Masahiro Kikuchi, et al.
出版: (2024-09-01)

Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect
由: Azuma Watanabe, et al.
出版: (2023-10-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
由: K. L. Raikhelson, et al.
出版: (2024-05-01)

The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review
由: Chavdar S. Pavlov, et al.
出版: (2024-05-01)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
由: Katharina Staufer, et al.
出版: (2023-07-01)

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients
由: Ryosuke Sugimoto, et al.
出版: (2023-02-01)

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study
由: Hidekatsu Yanai, et al.
出版: (2022-02-01)

The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis
由: Yvonne Burmeister, et al.
出版: (2023-12-01)

Editorial: Community series - liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies, volume II
由: Ana Sandoval-Rodriguez, et al.
出版: (2024-02-01)

Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
由: Renuka Suvarna, et al.
出版: (2024-08-01)

The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients
由: Natasa Paklar, et al.
出版: (2023-11-01)

Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease
由: Takao Miwa, et al.
出版: (2024-06-01)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
由: Takeshi Hatanaka, et al.
出版: (2021-10-01)

Prevalence of metabolically associated steatotic liver disease in the elderly: analysis and perspectives
由: O. O. Karshina
出版: (2025-01-01)

The rationale for the aggressive progression of MASLD in patients with type 2 diabetes
由: Valeria Michelle Fernández-Garibay, et al.
出版: (2025-01-01)

Comparison of clinical, biochemical and histological features of alcoholic steatohepatitis and non-alcoholic steatohepatitis in Asian Indian patients
由: Singh Deepak, et al.
出版: (2010-07-01)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
由: Gi-Ae Kim, et al.
出版: (2023-10-01)

Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake
由: Emil Deleuran Hansen, et al.
出版: (2025-01-01)

A Comprehensive Assessment of Liver Transplant Trends and Outcomes Among Adults With Steatotic Liver Disease in the U.S.
由: Shyam Patel, et al.
出版: (2025-01-01)

Long-Term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD
由: Takanobu Iwadare, et al.
出版: (2024-05-01)

A new name for an old problem. Metabolic dysfunction-associated steatotic liver disease - review of literature
由: Adrian Kruszewski, et al.
出版: (2024-07-01)

A social media listening study of patients’ experiences relating to metabolic dysfunction-associated steatotic liver disease: The LISTEN-MASLD study
由: Jeffrey V. Lazarus, et al.
出版: (2025-01-01)

Glycyrrhizinic Acid and Phosphatidylcholine Combination as a Preventive Therapy for Experimental Murine Non-Alcoholic Steatohepatitis
由: Veronika A. Prikhodko, et al.
出版: (2024-01-01)

Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis
由: Maryam Mahjoubin-Tehran, et al.
出版: (2021-08-01)

Case series showing the safety and changes in lipid profiles of hemodialysis patients with hypertriglyceridemia after pemafibrate administration
由: Rino Okada, et al.
出版: (2024-12-01)

Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease
由: Mira Thing, et al.
出版: (2024-01-01)

Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation
由: Kristoffer Kjærgaard, et al.
出版: (2024-03-01)

Liver Injury and Cell Survival in Non-Alcoholic Steatohepatitis Regulated by Sex-Based Difference through B Cell Lymphoma 6
由: Akihide Kamiya, et al.
出版: (2022-11-01)

Revolutionizing cardiometabolic health: the dual power of GLP-1 receptor agonists and SGLT2 inhibitors: a review article
由: G. Tomova-Lyutakova, et al.
出版: (2024-12-01)

Hypertransaminasemia and severe hepatic steatosis without inflammation. A case report
由: Nahum Méndez-Sánchez, MD, PhD, et al.
出版: (2003-10-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
由: Yu-Ming Cheng, et al.
出版: (2024-12-01)

Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?
由: Ju Hyun Shim
出版: (2020-04-01)

Epidemiologic features of non-alcoholic fatty liver disease in Russia
由: O. M. Drapkina, et al.
出版: (2014-10-01)

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
由: Reddemma Sandireddy, et al.
出版: (2024-07-01)

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
由: Gong Feng, et al.
出版: (2025-03-01)

Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
由: Jessica M. Rubino, et al.
出版: (2025-01-01)